|
Ono Pharmaceutical Co., Ltd. is a pharmaceutical company that develops, manufactures, and sells prescription and over-the-counter medicines. The group operates as a single pharmaceutical segment and focuses on research and development for therapeutic drugs. Key subsidiaries include Deciphera Pharmaceuticals, Inc., which handles clinical development, manufacturing, and sales, and Ono Pharmaceutical Healthcare, Toyo Pharmaceutical Chemical, and B-Brand Medical Dental, which engage in manufacturing and sales. The company also conducts import and export activities through Ono Pharma USA Inc. and Ono Pharma UK Limited. Regional sales and support are managed by subsidiaries in South Korea and Taiwan. The group includes investment entities such as Ono Venture Investment Inc. and Ono Digital Health Investment, as well as Ono Global Reinsurance, Inc. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage ono-pharma.com |
| Sector Healthcare | IR page ono-pharma.com/ja | |
|
Tags
prescription drugs, over-the-counter medicines, clinical development, pharmaceutical manufacturing, pharmaceutical sales, import and export, venture investment, digital health, Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Healthcare, Toyo Pharmaceutical Chemical, B-Brand Medical Dental, Ono Pharma USA Inc., Ono Pharma UK Limited, Ono Venture Investment Inc., Ono Venture Investment Fund I LP, Ono Digital Health Investment, Ono Pharma UDI, michiteku, Ono Global Reinsurance Inc.
|
Press page ono-pharma.com/ja/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 1.164T |
| Market cap (USD) | $ 7.273B |
| P/E | 14.70 |
| PEG | — |
| P/BV | 1.32 |
| P/S | 2.37 |
| P/OCF | 8.78 |
| P/FCF | 6.93 |
| Dividend yield | 3.4% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 8.5% |
| ROI | 8.1% |
| ROIC | 8.1% |
| Profit margin | 13.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -14.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 69 |
| Quality score | 0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 515.785B | 486.871B | 502.672B | 447.187B | 361.361B | 309.284B | 292.42B | 288.634B | 261.836B | 244.797B | 160.284B | 135.775B | 143.247B | 142.806B |
| Net profit | 69.767B | 50.047B | 127.977B | 112.723B | 80.519B | 75.425B | 59.704B | 51.539B | 50.284B | 55.793B | 24.979B | 12.976B | 20.344B | 22.927B |
| Free cash flow | 130.797B | 77.028B | 89.831B | 145.113B | 49.552B | 53.684B | 51.712B | 37.172B | — | — | — | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 2.511K | 1.606K | 2.453K | 2.765K | 3.066K | 2.892K | 2.489K | 2.167K | 3.297K | 2.305K | 4.765K | 2.715K | 1.787K | 1.146K |
| Price performance 12m | 0.56 | -0.35 | -0.11 | -0.1 | 0.06 | 0.16 | 0.15 | -0.34 | 0.43 | -0.52 | 0.76 | 0.52 | 0.56 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Borrowings, current (JPY) | — | 392M | 435M | — | — | — | — | — | 30B | 35.4B |
| Borrowings, non-current (JPY) | — | 320M | 1.77B | — | — | — | — | — | 105B | 75B |
| Lease liabilities (JPY) | — | — | — | 8.36B | 9.05B | 8.8B | 9.17B | 8.86B | 11.7B | 10.5B |
| Cash and deposits (JPY) | 146B | 65.3B | 60B | 69B | 61B | 69.1B | 96.1B | 166B | 205B | 237B |
| Intangible assets (JPY) | — | 55.7B | 63.1B | 66.4B | 70.3B | 64.7B | 69.1B | 57.3B | 330B | 354B |
| Net debt (borrowings + leases - cash) (JPY) | — | -64.6B | -57.8B | — | — | — | — | — | -57.9B | -116B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 74.5B | 15.7B | 66.8B | 74.2B | 74B | 61.8B | 160B | 111B | 82.5B | 137B |
| Purchases of property, plant and equipment (JPY) | — | -15.6B | -22.3B | -7.48B | -7.02B | -5.5B | -5.34B | -4.02B | -5.43B | -6.02B |
| Purchases of intangible assets (JPY) | — | -14.2B | -7.3B | -15B | -13.3B | -6.78B | -9.16B | -16.8B | -2.56B | -47.2B |
| Change in inventories (cash effect) (JPY) | — | -5.97B | -1.57B | -173M | -6.11B | -2.46B | -2.95B | -3.42B | 12.4B | 19B |
| Dividends paid (cash effect) (JPY) | — | -23.4B | -21.8B | -22.8B | -22.4B | -27.7B | -29.7B | -37.2B | -37.5B | -37.5B |
| Share buybacks (cash effect) (JPY) | — | -38.8B | -1M | -29.6B | -3M | -30B | -1M | -50B | -1M | -1M |
| Interest paid (cash effect) (JPY) | — | -14M | -27M | -76M | -73M | -70M | -74M | -92M | -1.41B | -2.16B |
| Income taxes paid (cash effect) (JPY) | — | -36.4B | -18.4B | -28.4B | -34.1B | -34.3B | -6.64B | -56.4B | -44.1B | -16.4B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | — | -14.1B | 37.2B | 51.7B | 53.7B | 49.6B | 145B | 89.8B | 74.5B | 83.6B |
| Income detail | ||||||||||
| Research and development expense (JPY) | — | 68.8B | 70.2B | 66.6B | 62.5B | 76B | 95.5B | 112B | 150B | 147B |
| ↳ 5y CAGR | +6.8% | +9.9% | +17.6% | +18.7% | ||||||
| Total comprehensive income (JPY) | 68.1B | 67.6B | 50.8B | 57.6B | 95.6B | 79.6B | 116B | 138B | 28.9B | 104B |
| Comprehensive income to owners (JPY) | — | 67.5B | 50.7B | 57.5B | 95.5B | 79.4B | 116B | 138B | 28.8B | 104B |
| Reported | Jun 30, 2017 | Jun 21, 2019 | Jun 21, 2019 | Jun 19, 2020 | Jun 18, 2021 | Jun 24, 2022 | Jun 23, 2023 | Jun 21, 2024 | Jun 19, 2025 | Jun 15, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
2026.11.05
研究開発
真性多血症を対象として開発中のSapablursen、欧州でもOrphan Medicinal Product Designationの指定を取得 -第3相臨床試験デザインを第68回米国血液学会年次総会にて発表-
- 真性多血症を対象に欧州、米国および日本で希少疾病用医薬品の指定を取得
- 真性多血症を対象としたグローバル第3相臨床試験(INTREPID試験)のデザインを、第68回米国血液学会年次総会で発表
小野薬品工業株式会社(本社:大阪市中央区、代表取締役社長COO:滝野 十一、以下「当社」)は、sapablursen(ONO-0530)が、真性多血症(PV)を対象として2026年10月には欧州においてOrphan Medicinal Product Designationの指定を取得したことを発表します。米国では、2024年1月にFast Track Designation、2024年8月にOrphan Drug Designation、2025年5月にBreakthrough Therapy Designationの指定を米国食品医薬品局(FDA)より受けています。さらに、日本では2026年9月に希少疾病用医薬品の指定を取得しています。
また、当社米国子会社のDeciphera社が実施しているsapablursenのPV患者を対象としたグローバル第3相臨床試験(INTREPID試験)の試験デザインを12月12~15日にルイジアナ州ニューオリンズで開催される第68回米国血液学会年次総会において、ポスター発表します。
発表内容は、下記の通りです。
演 題
Trial in Progress: INTREPID: A global, randomized, double-blind, placebo-controlled Phase 3 study of sapablursen in patients with phlebotomy-dependent polycythemia vera
発表者
Pankit Vachhani, M.D., Associate Professor of Medicine at O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham
発表形式
ポスター発表
発表日時
2026年12月13日(日) 午後6:00 - 8:00 (米国中部時間)
ポスター番号
3771
Sapablursenについて
Sapablursenは、Ionis社によって創製・開発されたTMPRSS6(ヘプシジン産生を負に調節する因子)を標的としたアンチセンス核酸医薬です。TMPRSS6の産生を抑制し、鉄恒常性の主要な調節因子であるヘプシジンの産生を増加させます。ヘプシジンの発現を増加させることにより、sapablursenはPVを始めとして様々な血液疾患の治療薬となる可能性があります。
真性多血症(PV)について
PVは、赤血球の過剰産生を特徴とし、生命を脅かす可能性のある希少な血液疾患です。特に肺、心臓、脳などの重要な臓器で重篤な血栓のリスクが大幅に増加します。PVの主な治療目標は、血中ヘマトクリット値を45%未満に維持し、血栓性イベントを防ぎ、重度の疲労、集中力の低下、夜間の発汗、かゆい症状などの負担を軽減することです。現在の治療法では、重度の症状や血中ヘマトクリット値のコントロールが不十分であるPV患者が存在します。
Deciphera Pharmaceuticals Inc.について
当社のグループ会社であるDeciphera社は、人々がより長く健康に生きられるよう革新的な医薬品の開発、販売に注力するバイオ医薬品企業です。先進的なキナーゼ阻害薬を始め、データ分析、AIを活用とした創薬技術などの最先端技術を活用して、当社の重点領域であるがん、免疫・炎症、神経領域の革新的な医薬品研究および、開発を加速させています。本社はマサチューセッツ州ウォルサムに置いており、カンザス州ローレンスに研究施設を設けています。Deciphera社は米国および欧州での当社事業の拡大を主導しており、当社製品のグローバル販売と強固なパイプラインの臨床開発の推進を図っています。詳細については、www.deciphera.com をご覧いただくか、LinkedIn および X (@Deciphera)でフォローしてください。
COPYRIGHT © 2026 ONO PHARMACEUTICAL CO., LTD.
ALL RIGHTS RESERVED.
当社ウェブサイトでは、サイトの利便性向上のためにクッキーを使用しています。
クッキーの利用にご同意いただける場合は、「同意する」ボタンを押してください。個人情報は収集されません。
同意する
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Ono Pharmaceutical Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| IVAL | 2.07% | 291,159 | $ 4.55M | Nov 18, 2026 |
| DSTX | 0.76% | 24,400 | $ 358.512K | Jun 30, 2026 |
| DFIV | 0.14% | 1,991,596 | $ 30.97M | Nov 12, 2026 |
| AVIV | 0.11% | 143,300 | $ 2.237M | Nov 16, 2026 |
| AVSD | 0.07% | 16,400 | $ 255.986K | Nov 16, 2026 |
| AVDE | 0.04% | 445,100 | $ 6.948M | Nov 16, 2026 |
| DFIC | 0.04% | 352,900 | $ 5.488M | Nov 12, 2026 |
| DFSI | 0.03% | 23,301 | $ 362.339K | Nov 12, 2026 |
| DXIV | 0.02% | 3,800 | $ 59.091K | Nov 12, 2026 |
| NTSI | 0.02% | 7,500 | $ 110.198K | Jun 30, 2026 |
| DFAI | 0.02% | 258,243 | $ 4.016M | Nov 12, 2026 |
| DFAX | 0.02% | 161,330 | $ 2.509M | Nov 12, 2026 |








